Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62.

Novel 2,5-dioxoimidazolidine-based conformationally constrained analogues of KN62 (1) were developed as P2X7 receptor (P2X7R) antagonists using a rigidification strategy of the tyrosine backbone of 1. SAR analysis of the 2,5-dioxoimidazolidine scaffold indicated that piperidine substitution at the N3 position and no substitution at N1 position were preferable. Further optimization of the substituents at the piperidine nitrogen and the spacer around the skeleton resulted in several superior antagonists to 1, including 1-adamantanecarbonyl analogue 21i (IC50 = 23 nM in ethidium uptake assay; IC50 = 14 nM in IL-1β ELISA assay) and (3-CF3-4-Cl)benzoyl analogue (-)-21w (54 nM in ethidium uptake assay; 9 nM in IL-1β ELISA assay), which was more potent than the corresponding (+) isomer. Compound 21w displayed potent inhibitory activity in an ex vivo model of LTP-induced pain signaling in the spinal cord and significant anti-inflammatory activity in in vivo models of carrageenan-induced paw edema and type II collagen-induced joint arthritis.

[1]  M. Lynch,et al.  Activation of the P2X7 receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1 , 2012, Journal of neurochemistry.

[2]  E. Keystone,et al.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine , 2012, Annals of the rheumatic diseases.

[3]  K. W. Jung,et al.  A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. , 2012, Drug discovery today.

[4]  K. Kang,et al.  Structure-activity relationships and optimization of 3,5-dichloropyridine derivatives as novel P2X(7) receptor antagonists. , 2012, Journal of medicinal chemistry.

[5]  C. Mebus,et al.  Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate , 2012, The Journal of Rheumatology.

[6]  A. Kalgutkar,et al.  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. , 2011, Bioorganic & medicinal chemistry letters.

[7]  Yu-Qiu Zhang,et al.  Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses , 2010, Brain, Behavior, and Immunity.

[8]  S. Senger,et al.  Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. , 2010, Bioorganic & medicinal chemistry letters.

[9]  R. Gay,et al.  Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[10]  M. Braddock,et al.  P2X7 Receptor-Mediated Release of Cathepsins from Macrophages Is a Cytokine-Independent Mechanism Potentially Involved in Joint Diseases , 2010, The Journal of Immunology.

[11]  Betsy S. Pierce,et al.  Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. , 2010, Bioorganic & Medicinal Chemistry Letters.

[12]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[13]  S. Skaper,et al.  The P2X7 purinergic receptor: from physiology to neurological disorders , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Yong‐Chul Kim,et al.  Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[15]  E. Gouaux,et al.  Crystal structure of the ATP-gated P2X4 ion channel in the closed state , 2009, Nature.

[16]  K. Ren,et al.  Role of interleukin-1β during pain and inflammation , 2009, Brain Research Reviews.

[17]  L. Alcaraz,et al.  Antagonists of the P2X(7) receptor. From lead identification to drug development. , 2009, Journal of medicinal chemistry.

[18]  Yong‐Chul Kim,et al.  Synthesis and structure-activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[19]  C. Leng,et al.  [Clinical effects of total knee arthroplasty in the treatment of ankylosed knee]. , 2008, Zhonghua yi xue za zhi.

[20]  P. Pelegrín.  Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. , 2008, Drug news & perspectives.

[21]  D. Spray,et al.  P2X7 receptor-Pannexin1 complex: pharmacology and signaling. , 2008, American journal of physiology. Cell physiology.

[22]  E. Tarcsa,et al.  Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[23]  O. Cruz-López,et al.  The P2X7 receptor as a therapeutic target , 2008, Expert opinion on therapeutic targets.

[24]  K. Jacobson,et al.  Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. , 2008, Bioorganic & medicinal chemistry letters.

[25]  Martin Braddock,et al.  Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors. , 2007, Journal of medicinal chemistry.

[26]  O. Cruz-López,et al.  From tyrosine to glycine: synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor. , 2007, Journal of medicinal chemistry.

[27]  M. Kassiou,et al.  Molecular probes for P2X7 receptor studies. , 2007, Current medicinal chemistry.

[28]  C. Gabel.  P2 purinergic receptor modulation of cytokine production , 2007, Purinergic Signalling.

[29]  A. Surprenant,et al.  Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor , 2006, The EMBO journal.

[30]  L. Jeong,et al.  Establishment of an assay for P2X7 receptor-mediated cell death. , 2006, Molecules and cells.

[31]  J. Dayer,et al.  Is IL-1 a good therapeutic target in the treatment of arthritis? , 2006, Best practice & research. Clinical rheumatology.

[32]  F. Di Virgilio,et al.  The P2X7 Receptor: A Key Player in IL-1 Processing and Release1 , 2006, The Journal of Immunology.

[33]  B. Sperlágh,et al.  P2X7 receptors in the nervous system , 2006, Progress in Neurobiology.

[34]  A. Michel,et al.  Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. , 2006, European journal of pharmacology.

[35]  P. Anand,et al.  Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain , 2005, Pain.

[36]  F. Di Virgilio,et al.  Recent progress in the discovery of antagonists acting at P2X7 receptor , 2005 .

[37]  E. Schwiebert,et al.  Large pore formation uniquely associated with P2X7 purinergic receptor channels. Focus on "Are second messengers crucial for opening the pore associated with P2X7 receptor?". , 2005, American journal of physiology. Cell physiology.

[38]  F. Di Virgilio,et al.  Agonists and antagonists acting at P2X7 receptor. , 2004, Current topics in medicinal chemistry.

[39]  F. Di Virgilio,et al.  Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. , 2003, Journal of medicinal chemistry.

[40]  K. Jacobson,et al.  Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization. , 2002, Bioconjugate chemistry.

[41]  R. North.  Molecular physiology of P2X receptors. , 2002, Physiological reviews.

[42]  K. Jacobson,et al.  Potent P2X7 receptor antagonists: Tyrosyl derivatives synthesized using a sequential parallel synthetic approach , 2001, Drug development research.

[43]  F. Di Virgilio,et al.  Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor. , 2000, Bioorganic & medicinal chemistry letters.

[44]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[45]  E. Kawashima,et al.  Tissue distribution of the P2X7 receptor , 1997, Neuropharmacology.

[46]  C. Gargett,et al.  The isoquinoline derivative KN‐62 a potent antagonist of the P2Z‐receptor of human lymphocytes , 1997, British journal of pharmacology.

[47]  E. Kawashima,et al.  The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7) , 1996, Science.

[48]  Manjinder Singh,et al.  Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy. , 2014, Bioorganic & medicinal chemistry.

[49]  J. Watters,et al.  Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. , 2010, Recent patents on CNS drug discovery.